Bemfola 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IB/0043 
B.IV.1.a.1 - Change of a measuring or administration 
09/01/2024 
PL 
device - Addition or replacement of a device which is 
not an integrated part of the primary packaging - 
Device with CE marking 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
IAIN/0042/G 
This was an application for a group of variations. 
08/11/2023 
n/a 
B.II.g.3 - Deletion of an approved change 
management protocol related to the finished product 
A.7 - Administrative change - Deletion of 
manufacturing sites 
IB/0041/G 
This was an application for a group of variations. 
26/04/2023 
n/a 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
A.7 - Administrative change - Deletion of 
manufacturing sites 
IB/0040 
C.I.2.a - Change in the SPC, Labelling or PL of a 
16/12/2022 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0039 
C.I.11.z - Introduction of, or change(s) to, the 
13/10/2022 
n/a 
Page 2/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IB/0038/G 
This was an application for a group of variations. 
12/07/2022 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IB/0037 
B.II.g.5.c - Implementation of changes foreseen in 
15/06/2022 
n/a 
an approved change management protocol - For a 
biological/immunological medicinal product 
PSUSA/1463/
Periodic Safety Update EU Single assessment - 
10/06/2022 
n/a 
PRAC Recommendation - maintenance 
202110 
follitropin alfa 
N/0036 
Minor change in labelling or package leaflet not 
19/05/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0034/G 
This was an application for a group of variations. 
21/12/2021 
n/a 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
Page 3/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
control/testing takes place 
IB/0032 
B.II.d.2.d - Change in test procedure for the finished 
13/12/2021 
n/a 
product - Other changes to a test procedure 
(including replacement or addition) 
IB/0033 
B.I.b.2.a - Change in test procedure for AS or 
28/10/2021 
n/a 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
IA/0031/G 
This was an application for a group of variations. 
30/09/2021 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.II.e.6.b - Change in any part of the (primary) 
packaging material not in contact with the finished 
product formulation - Change that does not affect 
the product information 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
Page 4/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
II/0029 
B.II.g.2 - Introduction of a post approval change 
28/05/2021 
n/a 
management protocol related to the finished product 
IA/0030 
A.7 - Administrative change - Deletion of 
17/03/2021 
n/a 
manufacturing sites 
II/0027 
B.II.b.1.c - Replacement or addition of a 
15/10/2020 
n/a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch 
release/control, and secondary packaging, for 
biol/immunol medicinal products or pharmaceutical 
forms manufactured by complex manufacturing 
processes 
IA/0026 
A.7 - Administrative change - Deletion of 
08/07/2020 
n/a 
manufacturing sites 
II/0025/G 
This was an application for a group of variations. 
25/06/2020 
n/a 
B.I.a.1.j - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS -  
Replacement or addition of a site where batch 
Page 5/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
control/testing takes place and any of the test 
method at the site is a biol/immunol method 
B.II.b.2.b - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place for a biol/immunol 
product and any of the test methods at the site is a 
biol/immunol method 
IA/0024 
B.II.c.3.z - Change in source of an excipient or 
13/03/2020 
n/a 
reagent with TSE risk - Other variation 
IB/0023/G 
This was an application for a group of variations. 
05/02/2020 
n/a 
B.II.b.1.z - Replacement or addition of a 
manufacturing site for the FP - Other variation 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
II/0022 
B.II.g.2 - Introduction of a post approval change 
30/01/2020 
n/a 
management protocol related to the finished product 
PSUSA/1463/
Periodic Safety Update EU Single assessment - 
14/06/2019 
n/a 
PRAC Recommendation - maintenance 
201810 
follitropin alfa 
II/0021/G 
This was an application for a group of variations. 
07/03/2019 
n/a 
B.II.b.2.b - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Page 6/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Replacement/addition of a site where batch 
control/testing takes place for a biol/immunol 
product and any of the test methods at the site is a 
biol/immunol method 
B.II.b.2.b - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place for a biol/immunol 
product and any of the test methods at the site is a 
biol/immunol method 
R/0019 
Renewal of the marketing authorisation. 
20/09/2018 
12/11/2018 
SmPC, Annex 
II, Labelling 
and PL 
II/0016 
Update of the RMP version 2 based on the phase-3 
14/06/2018 
n/a 
multicentre study conducted to compare the efficacy 
and safety of two r-hFSH formulations in normal 
ovulatory women 35 to 42 years of age undergoing 
in vitro fertilisation (IVF) (CSR FIN3002). 
C.I.11.b - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
change(s) which require to be further substantiated 
by new additional data to be submitted by the MAH 
where significant assessment is required 
IA/0018 
B.II.e.6.b - Change in any part of the (primary) 
13/06/2018 
n/a 
packaging material not in contact with the finished 
product formulation - Change that does not affect 
the product information 
Page 7/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N/0017 
Minor change in labelling or package leaflet not 
15/05/2018 
23/07/2018 
Labelling and 
connected with the SPC (Art. 61.3 Notification) 
PL 
IB/0015 
B.II.b.3.z - Change in the manufacturing process of 
04/12/2017 
n/a 
the finished or intermediate product - Other variation 
IA/0014 
A.7 - Administrative change - Deletion of 
20/10/2017 
23/07/2018 
Annex II and 
manufacturing sites 
PL 
IB/0013 
C.I.2.a - Change in the SPC, Labelling or PL of a 
09/08/2017 
23/07/2018 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0012/G 
This was an application for a group of variations. 
23/06/2017 
23/07/2018 
Annex II, 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
Labelling and 
PL 
II/0011 
B.II.b.1.c - Replacement or addition of a 
23/02/2017 
n/a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch 
Page 8/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
release/control, and secondary packaging, for 
biol/immunol medicinal products or pharmaceutical 
forms manufactured by complex manufacturing 
processes 
T/0010 
Transfer of Marketing Authorisation 
25/10/2016 
21/11/2016 
SmPC, 
Labelling and 
PL 
IA/0009 
B.II.e.6.b - Change in any part of the (primary) 
14/09/2016 
n/a 
packaging material not in contact with the finished 
product formulation - Change that does not affect 
the product information 
PSUSA/1463/
Periodic Safety Update EU Single assessment - 
09/06/2016 
n/a 
PRAC Recommendation - maintenance 
201510 
follitropin alfa 
N/0007 
Minor change in labelling or package leaflet not 
04/11/2015 
21/11/2016 
PL 
connected with the SPC (Art. 61.3 Notification) 
IAIN/0006/G 
This was an application for a group of variations. 
02/06/2015 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.e.7.b - Change in supplier of packaging 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
IA/0005 
B.II.e.6.b - Change in any part of the (primary) 
07/04/2015 
n/a 
packaging material not in contact with the finished 
product formulation - Change that does not affect 
Page 9/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the product information 
IA/0004 
B.II.e.7.b - Change in supplier of packaging 
17/03/2015 
n/a 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
IAIN/0003 
C.I.8.a - Introduction of or changes to a summary of 
23/12/2014 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
IB/0001/G 
This was an application for a group of variations. 
12/08/2014 
03/07/2015 
SmPC, Annex 
II, Labelling 
and PL 
A.1 - Administrative change - Change in the name 
and/or address of the MAH 
A.5.a - Administrative change - Change in the name 
and/or address of a manufacturer/importer 
responsible for batch release 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
Page 10/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
